NEW YORK, April 6, 2026, 11:26 EDT
Between April 3 and April 6, a trio of reports drawing on fourth-quarter 13F filings detailed that Aberdeen Group, Raab & Moskowitz Asset Management, and Stratos Wealth Partners each cut back on Pfizer positions—together unloading 740,174 shares. On Monday, Pfizer stock slipped roughly 0.7% to $28.12 in U.S. trading.
The timing is what stands out here, not so much the dollar amounts. These latest disclosures shed light on year-end moves as Pfizer makes its pitch to investors, aiming to offset declining COVID sales with a pipeline of new drugs and hopes for more reliable growth.
The 13F filing, a quarterly report required in the U.S., details which securities large asset managers held at a quarter’s close. The latest batch came in this January, reflecting positions as of Dec. 31—so these disclosures trail real activity, not offering a live view.
Aberdeen led the way, unloading 664,801 shares—a reduction of 11.3%—and closed out the quarter holding 5.2 million Pfizer shares, a stake valued at around $129.6 million. Raab & Moskowitz moved out 39,910 shares, while Stratos shed 35,463. Still, combined, the trio ended up with about 5.66 million shares between them, worth approximately $140.9 million as the year wrapped up.
The numbers have picked up, too. In February, the drugmaker topped fourth-quarter expectations—$17.56 billion in revenue, adjusted profit of 66 cents a share. It stuck with its 2026 revenue forecast of $59.5 billion to $62.5 billion. Just last week, a Belgian court ruled Poland and Romania must pay up on 1.9 billion euros ($2.2 billion) worth of COVID vaccine agreements.
Growth is trickier. Pfizer is aiming for its first obesity drug approval by 2028, with more than 20 obesity trials set to move forward this year. Chief Executive Albert Bourla brushed off pricing concerns, pointing to Eli Lilly and Novo Nordisk as market leaders. Daniel Barasa, portfolio manager at Gabelli Funds, described the early Pfizer data as “good, but not category-defining.” Reuters
Still, a key risk remains. After Dec. 31, Pfizer pulled the plug on a major U.S. trial of its updated COVID vaccine in healthy adults ages 50 to 64, citing poor enrollment. Jesse Goodman, former FDA chief scientist, didn’t mince words: “Without the data, there probably just won’t be a presentation.” Reuters
The filings stop short of signaling a full exit. Despite cutting back, the trio of investors were still sitting on roughly $140.9 million in Pfizer shares at the end of the year. With Pfizer’s market cap hovering near $135 billion as of Monday’s close, the open question now is whether the company’s newer assets can pull enough weight to counter the shrinking COVID segment.
